Log in

Athersys Stock Price, News & Analysis (NASDAQ:ATHX)

$1.37
+0.05 (+3.79 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$1.31
Now: $1.37
$1.38
50-Day Range
$1.27
MA: $1.37
$1.50
52-Week Range
$1.20
Now: $1.37
$2.17
Volume381,864 shs
Average Volume480,521 shs
Market Capitalization$209.17 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.29 million
Book Value$0.30 per share

Profitability

Net Income$-24,280,000.00
Net Margins-458.03%

Miscellaneous

Employees75
Market Cap$209.17 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.


Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) issued its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.03. The biopharmaceutical company earned $4.26 million during the quarter. Athersys had a negative return on equity of 106.93% and a negative net margin of 458.03%. View Athersys' Earnings History.

When is Athersys' next earnings date?

Athersys is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Athersys.

What price target have analysts set for ATHX?

2 Wall Street analysts have issued 12-month price targets for Athersys' stock. Their predictions range from $8.00 to $11.00. On average, they expect Athersys' share price to reach $9.50 in the next year. This suggests a possible upside of 593.4% from the stock's current price. View Analyst Price Targets for Athersys.

What is the consensus analysts' recommendation for Athersys?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.

What are Wall Street analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:
  • 1. Maxim Group analysts commented, "Athersys reported 1Q19 with revenue of $1.4M (license fees, grants, and collaborative revenue), and a net loss of ($13M). The company ended 1Q19 with $51M in cash on the balance sheet. We note that expenses are rising as the MultiStem programs expand. Athersys should have runway into 2020." (5/9/2019)
  • 2. According to Zacks Investment Research, "Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD). " (3/19/2019)

Has Athersys been receiving favorable news coverage?

Press coverage about ATHX stock has trended negative this week, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Athersys earned a news sentiment score of -2.6 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Athersys.

Who are some of Athersys' key competitors?

What other stocks do shareholders of Athersys own?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
  • Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
  • Karen Hunady, Director of Corp. Communications & Investor Relations

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.37.

How big of a company is Athersys?

Athersys has a market capitalization of $209.17 million and generates $24.29 million in revenue each year. The biopharmaceutical company earns $-24,280,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Athersys employs 75 workers across the globe.View Additional Information About Athersys.

What is Athersys' official website?

The official website for Athersys is http://www.athersys.com/.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]


MarketBeat Community Rating for Athersys (NASDAQ ATHX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  558
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Featured Article: Is the QQQ ETF safe?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel